- HOME
- SMB·BIO
-
South Jeolla-Gwangju region launches nation's largest regional venture mother fund
Government injects 75 billion won into fund; banks, universities and companies join as contributors Sub-fund investment program to launch in December, targeting 200 billion won total Korea Venture Investment opens southwest regional center A 131.3 billion won ($96.9 million) venture mother fund — the largest regional integrated mother fund in the country — has been launched to foster venture companies and startups in the South Jeolla-Gwangju integrated special city. The government, local authorities, financial institutions, universities and companies are jointly participating, with plans to build a venture fund totaling 200 billion won. The Ministry of SMEs and Startups said Wednesday it held a launch ceremony for the South Jeolla-Gwangju Regional Growth Fund at the gymnasium of Sunchon National University. The fund is the last regional growth fund to be established this year, following those for North Jeolla Province, Ulsan, Daejeon and the Daegu-North Gyeongsang Province region. It was created to focus investment on promising venture companies and startups in the South Jeolla-Gwangju integrated special city. The mother fund totals 131.3 billion won. The government's Korea Fund of Funds contributed 75 billion won, with local governments including the South Jeolla-Gwangju integrated special city, Yeosu, Suncheon and Gwangyang also participating. From the financial sector, Industrial Bank of Korea, Kwangju Bank, NH NongHyup Bank and Hana Bank joined as contributors. Regional universities — including Gwangju Institute of Science and Technology, Chonnam National University, Sunchon National University, Mokpo National University and Chosun University — as well as companies and institutions including Posco also took part. The ministry plans to determine specific investment areas through a steering committee composed of Korea Venture Investment, the South Jeolla-Gwangju integrated special city and key contributing institutions. It aims to launch a sub-fund investment program in December and build a venture fund totaling 200 billion won. Financial support for regional venture companies will also be strengthened. On Wednesday, Kwangju Bank, Jeonbuk Bank, Korea Venture Investment and Korea Technology Finance Corporation signed an MOU on productive financial cooperation to activate the southwest regional venture fund and venture ecosystem. The four institutions agreed to establish a comprehensive venture finance support system linking investment, loans and guarantees, and to help regional companies secure funding. Korea Venture Investment also expanded its regional investment presence. The Korea Venture Investment Southwest Regional Investment Center officially opened in the South Jeolla-Gwangju integrated special city Wednesday morning. The Southwest Regional Investment Center is the second regional investment center to open, following the Southeast Regional Investment Center in Busan. It will connect regional venture companies and startups with venture capital firms and support the discovery of promising companies and the attraction of investment. The regional growth fund is structured so that the government, local authorities and the private sector jointly contribute capital to create a pool for investing in regional companies. The 131.3 billion won raised is the mother fund that will be committed to sub-funds; additional capital from private investors such as venture capital firms will be brought in to build the actual investment fund of 200 billion won. The broader impact on investment in regional companies is expected to take shape as sub-funds are formed and investments are deployed. The launch ceremony was held in conjunction with the opening of the 2026 South Jeolla-Gwangju Startup Festival, a two-day event beginning Wednesday. A forum was also held to share the current state of the regional startup and venture ecosystem and discuss future directions. "We will expand the long-term growth capital supply and investment attraction support for regional venture companies and startups, based on the regional growth fund and Korea Venture Investment's regional investment centers, to build a sustainable regional venture ecosystem," said No Yong-seok, first vice minister of SMEs and Startups.
Nov. 11, 2026
-
Gov't to nurture 20 AI startups valued at W1tr or more by 2030
Goal includes 1 decacorn, 20 unicorns in AI sector Selected startups to receive more than 10 billion won each Support to cover R&D, tech validation, investment and overseas expansion Ministry of SMEs and Startups, National AI Strategy Committee unveil joint plan The government plans to nurture 20 AI startups with valuations of at least 1 trillion won ($738 million) by 2030, selecting high-potential companies for intensive support spanning research and development, investment attraction and overseas expansion. The initiative also sets a goal of producing at least one decacorn — a company valued at 10 trillion won or more. The Ministry of SMEs and Startups unveiled the plan, titled "AI Startup Beyond Unicorn Nurturing Strategy," on Wednesday at the Grand Hyatt Seoul in Yongsan-gu, Seoul, during the "Deep Dive Into 2026" conference. The strategy was jointly developed with the National AI Strategy Committee. The strategy focuses not merely on identifying promising AI startups but on developing them into globally competitive companies. To that end, the government will pursue three core strategies — full-cycle support, accelerated innovation growth and promotion of global market entry — broken down into 12 detailed tasks. The government, universities, research institutions and the private sector will collaborate to identify a pool of AI startups with unicorn potential. From that pool, companies ranking in the top 20 percent by investment and employment metrics will be selected for concentrated support. Selected companies will be assigned performance targets tied to each stage of growth and will receive support to strengthen their technology commercialization capabilities. Companies that advance to the final stage of the program can receive more than 10 billion won per company in R&D and commercialization funding. Tailored support for technology validation and investment attraction will also be provided in parallel. The plan also calls for industry-specific support. The government will connect demand-side companies with startups along the value chains of five key sectors — including manufacturing and biotech — and will establish a joint AI unicorn development control tower with the National AI Strategy Committee. Funding supply will also be expanded. AI-related funds, including the Next-Generation Unicorn Project and the National Growth Fund, will be deployed according to each startup's stage of development to help companies attract investment. The strategy also aims to strengthen cooperation across the AI industry ecosystem, from semiconductors and cloud infrastructure to large language models and services. Fabless chip designers, AI solution companies and demand-side firms will be grouped into a single cooperative body to pursue joint design and technology validation. To help startups secure early customers for their technologies, the government's existing "Government First Validation and Purchase" program — under which government agencies and public institutions serve as initial buyers — will be expanded to cover the AI sector. A separate track will apply startup technologies to large companies' products for performance verification, with the aim of converting that into actual purchases. Support for overseas expansion will also be strengthened. Country-specific "AI connectors" will be established to facilitate technology transactions between domestic startups and overseas buyers, and the government will work with the Public Procurement Service to create opportunities for domestic AI technologies to be validated at overseas institutions. The ministry also plans to connect domestic and international AI specialists with promising startups and to support the hiring and secondment of research personnel. The strategy is significant in that it shifts the emphasis of AI startup support from early-stage technology development to tangible business growth. The government intends to link not only R&D funding but also technology validation, procurement, investment and overseas market access into a single support framework. However, the more-than-10-billion-won per-company figure applies only to those that advance to the final stage of the program, meaning the actual scope and scale of support will vary depending on each company's growth stage and performance. At the event, Minister of SMEs and Startups Lee So-young held an open dialogue on AI startup growth strategies with representatives and experts from global AI companies, including US AI unicorn Human&, Japan's Sakana AI and domestic firm Wrtn Technologies. "For AI startups to grow into global unicorns, they need comprehensive support that goes beyond technology development — including commercialization through technology validation, investment, market access and overseas expansion," Lee said. "Through this strategy, we will provide intensive support so that companies in South Korea can grow not just into global AI unicorns but into decacorns." Deep Dive Into 2026, running Tuesday through Thursday, is a conference where deep tech startups share their technologies and growth strategies. This year's event is themed "AI Makes Sense" and features 36 programs across three areas — physical AI, agentic AI and AI for humanity. More than 140 global speakers and domestic and international experts are participating.
Nov. 11, 2026
-
Aribio completes global Phase 3 trial for oral Alzheimer's drug, to unveil top-line data Monday
52-week dosing across 13 countries wraps up with 1,535 patients enrolled; Korean firm self-funded trial with more than 150 billion won raised through regional licensing and Fosun Pharma option deal Aribio has completed the main Phase 3 trial of AR1001, its oral Alzheimer's disease treatment candidate, and is set to release final efficacy data in the coming days. The milestone is drawing attention as a rare case of a Korean pharmaceutical and biotech company completing a multinational Phase 3 trial while retaining full operational control, rather than relying solely on external technology transfers. According to industry sources, Aribio will present the top-line results of the AR1001 global Phase 3 trial at the Clinical Trials on Alzheimer's Disease conference (CTAD 2026) in Boston on Monday. AR1001 is an oral synthetic drug candidate designed for once-daily use in patients with early-stage Alzheimer's disease. It targets mechanisms that protect brain neurons and slow disease progression, and if commercialized, is expected to significantly improve patient convenience compared with existing injection-based treatments. The global Phase 3 trial enrolled 1,535 early-stage Alzheimer's patients across 13 countries, including the United States, European nations, South Korea and China. The trial compared AR1001 and placebo groups over 52 weeks. Of the enrolled patients, 1,348 — or 87.8 percent — completed the full 52-week dosing period. The last patient completed dosing on June 29, and 95.5 percent of those who finished the main trial have since enrolled in an extension study evaluating long-term safety. Aribio oversaw every stage of the trial through its US-based clinical operations team, from protocol design to management of trial sites and contract research organizations across participating countries. The company also raised more than 150 billion won ($112 million) through regional licensing agreements and other arrangements to self-fund the large-scale Phase 3 costs. Under a global licensing option agreement with China's Fosun Pharma, Aribio received $60 million. Last month, the first tranche of a separate equity investment — about 11.5 billion won — was also paid in, translating the commercialization partnership into tangible cash inflows. The primary focus at Monday's CTAD presentation will be the trial's main efficacy endpoint: whether AR1001 meaningfully slowed the decline of memory, judgment and daily functioning compared with placebo, and whether the results achieved statistical significance. Long-term safety data from extended dosing are also expected to be a key factor in regulatory approval decisions.
Nov. 11, 2026
-
GI Innovation heads to Jefferies London conference to advance global licensing deals
Company to hold one-on-one meetings with multinational drugmakers and investors on GI-214 and other pipeline candidates CEO Chang Myung-ho vows to 'produce tangible results' by deepening licensing talks for each pipeline GI Innovation, a developer of innovative new drugs, will attend Europe's largest healthcare investment event to advance licensing and partnership talks with global pharmaceutical companies. The company announced Wednesday that it will participate in the 2026 Jefferies Global Healthcare Conference, to be held in London from Nov. 16 to Nov. 19. Hosted annually by global investment bank Jefferies, the conference is the largest healthcare investment gathering in Europe. Pharmaceutical and biotech companies from around the world convene alongside major institutional investors to share the latest industry trends and explore strategic cooperation, including investment opportunities and co-development arrangements. During the event, GI Innovation will hold one-on-one partnering meetings with multiple global pharmaceutical companies and new institutional investors, covering GI-214 — its lead pipeline candidate — and several other drug candidates under ongoing discussion. The company said it plans to advance licensing negotiations and broadly explore opportunities to attract global investment. "We have a number of individual meetings scheduled at this conference covering multiple pipelines," Chief Executive Chang Myung-ho said. "We will deepen the licensing discussions we have been building and conduct in-depth negotiations tailored to the development stage and characteristics of each pipeline, with the goal of producing tangible commercialization results." The participation builds on the global drug development capabilities GI Innovation demonstrated through its recent clinical collaboration with Johnson & Johnson, and aims to put early-stage licensing negotiations for GI-214 and other follow-on pipeline candidates firmly on track with European investors and major pharmaceutical companies.
Nov. 11, 2026
-
Samsung Biologics' W2.7tr rights offering draws nearly 97% subscription rate
Existing shareholders subscribe at 98.7%, employee stock ownership plan at 89.3%; Samsung C&T and Samsung Electronics take up full allotments High per-share price and labor dispute fail to deter investors, with more than 30,000 shares oversubscribed Proceeds earmarked for PolyPeptide acquisition as company accelerates modality and global footprint expansion Samsung Biologics has cleared the final hurdle in its 2.7 trillion won ($2.01 billion) rights offering, drawing a subscription rate of nearly 97% and securing the bulk of its fundraising target. Despite a per-share issue price exceeding 1 million won and a second union strike adding to uncertainty, existing shareholders and employees turned out in force — a sign that investors are betting on the company's long-term growth prospects over near-term risks. According to filings with the Financial Supervisory Service's DART system Wednesday, Samsung Biologics received subscriptions for 2,198,146 of the 2.27 million shares on offer during the two-day subscription window that ran Monday through Tuesday, for an overall subscription rate of 96.83%. Breaking down the results by category, existing shareholders holding preemptive rights subscribed for 1,792,716 shares — including oversubscriptions — out of an allotment of 1,816,000 shares, for a subscription rate of 98.7%. Major shareholders Samsung C&T, with 782,818 shares, and Samsung Electronics, with 567,503 shares, each took up their full allotments following board approval, reaffirming the group's commitment to nurturing the affiliate. The employee stock ownership plan also posted strong participation, with 405,430 shares subscribed out of a priority allotment of 454,000, for a take-up rate of 89.3%. Shareholders back company despite strike risk, bet on core competitiveness The subscription results drew particular attention from the industry given the labor tensions surrounding the company. Samsung Biologics' mutual-benefit union launched a three-week second strike Friday, centered on indirect departments including quality control, quality assurance and logistics. Labor disputes are considered an especially sensitive risk for biopharmaceutical manufacturers, where flawless quality management and on-time supply are central to maintaining the trust of global clients. Even so, investors submitted more than 30,000 shares in oversubscriptions despite a confirmed issue price of 1.174 million won per share. The market, in effect, placed the company's solid fundamentals above concerns over temporary labor uncertainty or share dilution from the large new issuance. Industry observers say the trust shareholders showed reflects Samsung Biologics' track record of securing most of the world's top 20 pharmaceutical companies as clients, as well as its demonstrated ability to stabilize production through replacement staffing during labor actions. Analysts say investors concluded that short-term labor noise would not undermine the company's core value — its competitiveness in winning global contracts and its operational stability. 2.7 trillion won war chest secured as 'three-pillar expansion' gains momentum The full 2.665 trillion won raised through the rights offering will go toward acquiring PolyPeptide Group, a global peptide contract development and manufacturing organization. The deal is the largest pharmaceutical and biotech merger and acquisition in South Korean history. Samsung Biologics secured a 97.98% stake through a recent tender offer, surpassing the 90% threshold required to compulsorily acquire the remaining shares and effectively locking in full ownership. The strong subscription results put the company on stable footing to fund the acquisition. The company plans to use the acquisition as a springboard for its "three-pillar expansion" strategy, targeting simultaneous growth across production capacity, portfolio breadth and geographic reach. The deal will extend Samsung Biologics' modality coverage in one move — from its existing focus on antibody drugs, messenger RNA and antibody-drug conjugates into peptides, the key raw material for GLP-1-based obesity and diabetes treatments, one of the fastest-growing segments in the industry. In addition, the acquisition brings in six production sites and a research and development center spanning five countries including Europe, the United States and India, sharply expanding the company's global manufacturing footprint. The rights offering is structured as a shareholder allocation followed by a public offering of any unsubscribed shares. A public subscription for the remaining 71,854 shares will be held Thursday and Friday, with payment due Tuesday and new shares set to list on Nov. 30. Any shares left over after the public offering will be fully underwritten by the lead managers.
Nov. 11, 2026
-
Joa Pharmaceutical launches liquid magnesium product 'Mags Boost Up'
Company says rapid absorption delivers high bioavailability Joa Pharmaceutical launched Mags Boost Up, a high-dose liquid magnesium product, on Wednesday. The product contains 2,800 milligrams of glycerophosphate magnesium — equivalent to 350 milligrams of elemental magnesium — along with three types of B vitamins. The company said it carries the highest magnesium content among over-the-counter liquid magnesium products on the domestic market. Joa Pharmaceutical said the 2,800 milligrams of glycerophosphate magnesium per ampoule is effective in relieving symptoms of magnesium deficiency, including physical fatigue, reduced stamina and muscle cramps. The product also combines B vitamins to aid magnesium absorption in the body, supporting energy metabolism and the maintenance of muscles and nerves, the company said. As a liquid formulation, the product is rapidly absorbed by the body, enabling high bioavailability, the company said. It also features Joa's Sepi ampoule design for easy portability and convenient dosing. With the launch, Joa Pharmaceutical has rounded out its Mags magnesium brand to five products: Mags Boost Up, Mags Double Action Soft Capsule, Mags Soft Capsule, Mags Power and Mags Forte. The lineup gives consumers options based on their preferred dosage format.
Nov. 11, 2026
-
Samsung Electronics earns top co-growth rating for 15th straight year; 3 Hanwha units join S tier for first time
44 of 231 firms earn top S rating SK Telecom holds top grade for 14th year running SK Intellix posts biggest score gain IBK, Woori Bank named top in inaugural shared-finance assessment Samsung Electronics has received the top rating in the Shared Growth Index for the 15th consecutive year. SK Telecom maintained its top grade for the 14th straight year, while three Hanwha Group affiliates — Hanwha, Hanwha Systems and Hanwha Aerospace — earned the highest rating for the first time. The Commission on Shared Growth announced the results of its 2026 Shared Growth Index evaluation Wednesday morning at the Conrad Hotel in Yeouido, Seoul, during its 90th plenary session. This year's assessment covered 231 companies based on their performance last year. The Shared Growth Index measures the level of cooperative partnership at each company by combining the commission's own comprehensive co-growth evaluation with the Korea Fair Trade Commission's assessment of fair-trade agreement compliance. 44 firms earn top grade; Samsung Electronics leads with 15 straight years A total of 44 companies received the top S rating. The A (excellent) grade went to 69 companies, B (average) to 81, C (insufficient) to 24 and D (very insufficient) to 13. Companies earning the top grade included Samsung Electronics, SK Telecom, Hyundai Motor Company, Kia, Naver, Posco, LG Electronics, SK hynix, Nongshim and Lotte Department Store. Samsung Display, Samsung C&T's construction and fashion divisions, Samsung Electro-Mechanics, LG Chem, Hyundai Mobis and GS Engineering & Construction also received the highest rating. Samsung Electronics has held the top grade every year since the index was introduced 15 years ago. SK Telecom has done so for 14 consecutive years, while Hyundai Transys, KT Corp and SK Inc have each maintained the top rating for 12 straight years. LG Innotek and SK Ecoplant also kept the highest grade for the 10th year running. Twenty companies qualified as "honorary top-rated firms," a designation requiring three or more consecutive years at the top grade. Doosan Enerbility, Samsung C&T's fashion division, Samsung Electro-Mechanics, SK Siltron, GS Retail (GS25) and Hyundai Autoever were among six companies newly achieving three consecutive years at the top level. Five companies earned the top S rating for the first time this year: Hanwha, Hanwha Systems, Hanwha Aerospace, Lotte Duty-Free and Korea Seven. Companies receiving the A (excellent) grade included Ottogi, Amorepacific, E-mart, Hyundai Engineering & Construction, Hyundai Department Store, CJ Olive Young, LG H&H and LX Hausys. Meanwhile, 24 companies were rated C (insufficient), including Daedong, Autech Carrier, Coupang Inc, GM Korea, Hite Jinro and OB Beer. Thirteen companies were classified D (very insufficient), among them Das, Daebang Construction, KG Mobility, Seoul Semiconductor and TYM. Some 81 companies received the B (average) grade, including Korea Zinc, KleanNara, Yuhan-Kimberly, KCC Glass, Kolmar Korea, Cosmax and Hyundai Livart Furniture. Overall scores rise but SME satisfaction dips; SK Intellix posts biggest gain The average performance score for large companies rose 5.02 points, from 57.56 last year to 62.58 this year. Samsung Electronics and LG Electronics tied for the highest score. SK Intellix recorded the largest year-on-year improvement in performance score among all assessed companies, finishing the year with an A (excellent) rating. By contrast, the average score in the small and medium-sized enterprise satisfaction survey slipped 0.38 points, from 73.47 last year to 73.09 this year. Korea Seven received the highest satisfaction score, while Kyochon F&B posted the biggest year-on-year gain. Support figures for partner firms were also disclosed. One hundred large and mid-sized companies provided 1.18 trillion won ($882 million) in support to partner small and medium-sized enterprises, while 128 companies contributed 181.4 billion won to shared-growth cooperation funds. Another 140 companies paid 165.32 trillion won to 44,317 first-tier partner SMEs through a shared-payment system. The acceptance rate for supplier requests to raise unit prices or purchase amounts reached 98.3 percent, up 10.5 percentage points from 87.8 percent the previous year. Of the 3.51 trillion won in requested increases, 3.45 trillion won was in fact applied. IBK, Woori Bank named top performers in inaugural shared-finance assessment Industrial Bank of Korea and Woori Bank were named top performers in the pilot Shared Finance Index assessment, conducted for the first time this year. The Shared Finance Index is a system that comprehensively evaluates financial institutions on their efforts to support small and medium-sized enterprises and on SME satisfaction. Six banks — KB Kookmin, Industrial Bank of Korea, NH NongHyup, Shinhan, Woori and KEB Hana Bank — were assessed across three categories: shared-finance performance (40 points), shared-growth cooperation performance (40 points) and SME satisfaction survey (20 points). Commission Chairman Jang In-hwa said the Shared Growth Index evaluation is "a very important tool for encouraging companies to voluntarily pursue cooperative partnerships," adding that the commission would seek improvements to the system from multiple angles based on feedback from the field to strengthen its effectiveness. The commission plans to develop evaluation indicators that reflect the characteristics of individual industries and to consider expanding the assessment scope to second- and third-tier suppliers. It also intends to refine the Shared Finance Index metrics and gradually broaden the range of institutions covered. "We will expand the scope of shared growth into diverse sectors such as online platforms and the defense industry, and actively pursue cooperation with local governments," Jang added.
Nov. 11, 2026
-
Higher blood musclin levels linked to lower risk of muscle loss after colorectal cancer surgery, study finds
Yonsei University professors Ahn Chul-woo and Kang Jung-hyun lead research establishing link between preoperative blood musclin and post-surgical skeletal muscle changes; findings published in EJSO A new study suggests that the risk of skeletal muscle loss following colorectal cancer surgery can be predicted in advance through a preoperative blood test. A research team led by professors Ahn Chul-woo (endocrinology) and Kang Jung-hyun (colorectal surgery) at Yonsei University's Gangnam Severance Hospital — including researchers Kim Yu-sik, Nam Ji-sun, Shin Su-jin and Kim Young-hyun — found that higher preoperative blood musclin levels were associated with better preservation of skeletal muscle mass and a lower risk of muscle loss after colorectal cancer surgery. Patients who undergo cancer surgery frequently experience muscle loss due to malnutrition and reduced physical activity. Post-surgical skeletal muscle decline is a major factor that slows recovery and worsens prognosis. CT scans have traditionally been used to measure current muscle mass, but they have limitations in predicting how much muscle a patient may lose after surgery. Musclin, the protein the research team focused on, is a type of myokine — a hormone secreted primarily by skeletal muscle — and is known to be involved in maintaining skeletal muscle mass, supporting metabolic adaptation in muscle tissue and inhibiting protein breakdown. The team measured preoperative blood musclin concentrations and inflammatory markers in 106 colorectal cancer surgery patients at Gangnam Severance Hospital, with an average age of 63.3. Of those, 95 patients for whom pre- and post-operative CT follow-up was available were included in a retrospective analysis of changes in the skeletal muscle index based on third lumbar vertebra CT scans, taken at a median interval of 198 days (approximately 6.5 months). The analysis found that 28.4 percent of the tracked patients — 27 of 95 — experienced a post-surgical decline in the skeletal muscle index exceeding 5 percent. After adjusting for confounding variables including age, sex and inflammatory markers in a multivariate analysis, preoperative blood musclin levels showed a significant positive correlation with post-surgical skeletal muscle index (p=0.001). Each 1 ng/mL increase in preoperative blood musclin concentration was associated with a 0.529-fold reduction in the odds of post-surgical skeletal muscle loss exceeding 5 percent (odds ratio; p=0.038). When blood musclin levels were added to a predictive model for post-surgical skeletal muscle index that had previously relied only on clinical data and inflammatory markers, the model's explanatory power (R²) improved from 0.767 to 0.794. The researchers said this suggests musclin can provide additional information about muscle loss vulnerability that CT measurements and inflammatory markers alone cannot capture. The research team said the study is significant in that it extends musclin's role beyond a simple muscle-secreted hormone, positioning it as a candidate blood biomarker for identifying patients at high risk of post-surgical muscle loss before an operation. "Muscle is not merely an organ that moves the body — it is an endocrine organ that secretes signaling molecules reflecting the body's health status," said Professor Ahn. "This research demonstrates that musclin, a health signal sent by muscle, can serve as a new biomarker candidate reflecting metabolic adaptation and post-surgical muscle loss vulnerability in cancer patients." "Skeletal muscle loss after colorectal cancer surgery is directly linked to a patient's recovery and long-term treatment outcomes, but CT scans alone have made it difficult to identify in advance who will experience rapid muscle decline," said Professor Kang. "If we can use blood tests to screen high-risk patients for muscle loss before surgery, we expect it will be of great help in developing patient management strategies." The study was published in the European Journal of Surgical Oncology (EJSO), an international journal in the field of surgical oncology, under the title "Preoperative circulating musclin as a candidate biomarker of postoperative skeletal muscle vulnerability in colorectal cancer."
Nov. 11, 2026
-
LX Hausys wins US 'Home Reno Award,' showcasing design edge
Natural stone texture earns praise for design and durability Product designed for kitchen and bathroom countertops with easy maintenance LX Hausys has earned recognition in the US home remodeling market for an interior surface material that combines the look of natural stone with strong durability. The company announced Wednesday that its Viatera Solea product won the 2027 Home Reno Award presented by the American lifestyle magazine Good Housekeeping. The Home Reno Award recognizes products and services in the home remodeling sector that excel in design and functionality, selected through expert evaluation and testing. Viatera Solea features a white base with broad, subtle gold-toned veining that replicates the natural appearance of stone. Viatera is an engineered quartz surface material used primarily for kitchen countertops and bathroom vanity tops. Its durability and stone-like aesthetics have made it a popular choice, particularly as demand for premium interior finishes has grown in the North American market. Viatera Solea is engineered so that the veining pattern flows seamlessly across multiple slabs when installed side by side, creating the appearance of a single continuous surface over large areas. The product also resists scratches and stains from everyday use, making it easy to maintain. The award reflects the growing importance of durability and ease of maintenance alongside design in the interior materials market. It is particularly significant in high-use spaces such as kitchens and bathrooms, where materials that deliver the premium look of natural stone while reducing the burden of upkeep are increasingly valued. LX Hausys won the 2026 Home Reno Award last year with its porcelain surface material Teracanto Onyx Pearl, and the latest recognition for Viatera Solea marks the company's second consecutive win. "This award recognizes our efforts to provide innovative interior materials that combine sophisticated design with long-lasting functionality," a company official said. "We will continue to introduce differentiated products that balance design and practicality."
Nov. 11, 2026
-
Cha Biogroup's former chairman vows to treat incurable diseases, extend healthy lifespan with K-Cell
Cha Kwang-ryul delivers keynote at congress of 50-year-old international society in Busan, drawing collaboration inquiries from researchers worldwide; presentation covers donor screening, cell procurement and ovarian aging research Cha Kwang-ryul, director of the Global Research Institute at Cha Hospital and Cha Biogroup, laid out a vision for treating intractable diseases and extending healthy lifespan using K-Cell technology in a keynote address at the 16th World Congress of the International Society for Immunology of Reproduction, held at Bexco in Busan from Thursday to Sunday. The lecture drew an audience of 400 and generated a wave of collaboration inquiries from researchers around the world. The International Society for Immunology of Reproduction (ISIR), founded in 1975, is a leading international academic body in the field of reproductive immunology. Robert Edwards, who received the Nobel Prize in Physiology or Medicine for developing in vitro fertilization technology, was among its co-founders. The society serves as a forum where clinicians and researchers from around the world share findings on the interplay between the immune system and reproductive processes, including infertility, implantation and the maintenance of pregnancy. Since last year, Cha has been delivering lectures on K-Cell and longevity at academic conferences, universities and companies both in South Korea and abroad, promoting the country's stem cell and regenerative medicine research capabilities and its vision for future medicine. At this congress, Cha presented a concrete strategy for securing K-Cell resources and explored their potential applications in ovarian aging research for an audience of reproductive immunology specialists worldwide. In the lecture "Longevity & Reproductive Aging Using K-Cells," Cha identified the development of treatments for intractable diseases as K-Cell's primary goal. The plan calls for securing cells with the functional qualities required for each specific disease and applying them to treatment development, then expanding that work into longevity and life-extension research targeting aging. To that end, Cha outlined a detailed method for selecting donors whose cells are suited to therapeutic purposes. On top of standard eligibility assessments — including medical history reviews and infectious disease testing — the approach involves a comprehensive evaluation of the donor's age, clinical characteristics, three-generation family history and whole-genome sequencing data. The strategy is to analyze genetic variants associated with health maintenance as well as those that elevate disease risk, assess cell function, and thereby secure K-Cell resources suited to developing treatments for specific diseases. Cha also introduced methods of genetic modification and somatic cell nuclear transfer technology for obtaining superior stem cells. Somatic cell nuclear transfer is a technique in which the nucleus of a selected somatic cell is transplanted into an enucleated egg to produce embryonic stem cells. Cha presented an approach linking donor selection through to stem cell production to secure cell resources tailored to specific therapeutic purposes. Cha highlighted ovarian aging as a key area of research for longevity and life extension. Drawing on findings that women who reach menopause later tend to have greater longevity prospects, Cha said slowing ovarian aging could serve as an important research strategy for extending healthy lifespan and overall lifespan in women. Cha framed ovarian aging not merely as a matter of pregnancy and childbirth, but as a challenge connected to women's health and longevity across their entire lives. Cha also presented research Cha Hospital has accumulated in egg freezing and stem cell work, and shared the current status of a clinical study at Bundang Cha Hospital using umbilical cord-derived mesenchymal stem cells to treat premature ovarian insufficiency. Through this, Cha outlined the direction and future tasks of cell therapy research aimed at restoring ovarian function. Cha also introduced a strategy linking K-Cell procurement, production and clinical development around CGB (Cell Gene Bioplatform), a cell and gene therapy platform set to open in early next year. The plan involves building a cell bank of diverse stem cells and immune cells, then using AI to recommend and match cells suited to specific diseases and required functions, supplying them to researchers, hospitals and biotech companies worldwide. Cha Hospital and Cha Biogroup said they will continue to promote K-Cell's research direction and potential through international academic forums, prioritizing the development of treatments for intractable diseases while expanding into longevity and life-extension research.
Nov. 11, 2026
-
Bundang Seoul National University Hospital marks 10 years of Healthcare Innovation Park, unveils global cluster vision
Healthcare Innovation Park, opened in 2016 as South Korea's first hospital-centered bio cluster, serves as a hub for full-cycle research and development support Hospital aims to realize future medical innovation through expanded industry-academia-research-hospital collaboration Bundang Seoul National University Hospital held a joint symposium with Seoul National University Hospital on Tuesday at the Healthcare Innovation Park, marking the 10th anniversary of the facility and unveiling a new vision to become "a hospital-centered global innovation cluster leading the national bio-health innovation ecosystem." The symposium, co-hosted by the two hospitals, brought together officials and researchers from Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center and other institutions. Participants shared research achievements accumulated by each organization and explored avenues for expanding joint research. The event featured a 10th-anniversary ceremony for the Healthcare Innovation Park, a commemorative lecture and presentations of major research findings. The anniversary ceremony included a formal proclamation of the park's new vision. The Healthcare Innovation Park opened in 2016 as South Korea's first hospital-centered bio cluster and has since steadily expanded its research and clinical infrastructure. In 2019, the hospital completed the Ji Seok-yeong Biomedical Research Institute, establishing a research foundation linking basic science through preclinical and clinical stages. The park subsequently opened a simulation center, a clinical trial center and a challenge center, broadening its education and research support capabilities. Through these additions, it built a system supporting the full research and development cycle — from idea generation to commercialization — under one roof. In recognition of these research capabilities, Bundang Seoul National University Hospital received first-tier research-centered hospital certification from the Ministry of Health and Welfare in 2025. The Healthcare Innovation Park currently houses 30 bio-healthcare companies that collaborate with the hospital and research institutions in a shared space, and the park's cumulative patent count has reached 2,000. The new vision calls for expanding industry-academia-research-hospital collaboration, building on the research foundation the hospital has developed as a research-centered institution and on the cooperative environment the Healthcare Innovation Park provides. The goal is to translate research outcomes into changes at the clinical level and into industry applications, delivering tangible improvements in public health. The commemorative lecture featured Choi Byung-yun, head of research planning at Bundang Seoul National University Hospital, who spoke on "Ten Years of the Healthcare Innovation Park: Achievements and the Road Ahead," outlining the park's major accomplishments and future direction. Park Jeong-hwan, director of the medical AI and data policy division at the Ministry of Health and Welfare, shared the government's policy direction on health and medical data in the AI era and said closer ties between research and industry were essential. In the final session, researchers from the participating institutions presented major findings. Topics ranged from the current state and challenges of medical research at Seoul National University College of Medicine to clinical development of cell therapies, an advanced treatment platform for pancreatic cancer, and AI-based dementia prevention strategies — spanning basic research through clinical application. The participating institutions said they plan to use the symposium as a springboard to deepen collaboration by linking their respective research capabilities and infrastructure for expanded joint projects. "The Healthcare Innovation Park is embarking on a new leap forward, built on a decade of achievements," said Jeon Young-tae, director of Bundang Seoul National University Hospital. "We will do our utmost to ensure that outstanding research outcomes translate into real change at the clinical level and contribute to improving public health." Kim Jae-yong, director of the hospital's Biomedical Research Institute, said the new vision reflects a commitment to advancing toward a global innovation cluster where research, industry and clinical practice converge around the hospital, drawing on years of accumulated collaboration. "The Healthcare Innovation Park will serve as a solid foundation to ensure that the inter-institutional cooperation strengthened at this symposium leads to new joint research and medical innovation," Kim said.
Nov. 11, 2026
-
Sopung Connect hosts NHarvestX 2026 showcase as 7 agtech startups share AI breeding results
7 agtech firms collaborate with Nonghyup affiliates Companies propose technology adoption, purchases and further pilots Seven agricultural technology startups and affiliates of the National Agricultural Cooperative Federation, or Nonghyup, gathered to share the results of a six-month technology pilot covering AI-based crop breeding, smart farm environmental controls and agricultural byproduct recycling, and to discuss commercialization plans. Startup accelerator Sopung Connect said Wednesday it held the NHarvestX 2026 results showcase at On Dream So Society in Jung-gu, Seoul, on Tuesday. NHarvestX is a program that validates technologies and services developed by startups in real business environments, matched to the on-site needs of Nonghyup affiliates and related organizations. Sopung Connect manages the program, designing pilot projects and supporting collaboration between participating companies. Seven companies took part: Banseok Industrial, Robas, Alt2, FarmConnect, Power2Farms, Green Continue and Foparents. Robas piloted an AI-based integrated agricultural breeding data solution with Nongwoo Bio. FarmConnect worked with Nongso Agricultural Cooperative on AI agent-powered bee pollination farming consultations, while Power2Farms verified low-cost smart farm crop-layer environmental control technology with Namwon Agricultural Cooperative. About 70 people attended the event, including officials from the National Agricultural Cooperative Federation, the Korea Agency of Education, Promotion and Information Service for Food, Agriculture, Forestry and Fisheries, Nonghyup affiliates and related organizations, and investors from the Agricultural Mother Fund. Participating companies presented their pilot results and proposed follow-up cooperation to Nonghyup, including technology adoption, product purchases and expanded pilots. Investment linkage possibilities were also discussed through individual consultations. However, whether any purchase contracts or follow-on investments were finalized was not disclosed. "This is a program that connects Nonghyup's on-site needs with startup technology to verify applicability in real business environments," Sopung Connect CEO Choi Kyung-hee said. "We will continue to expand follow-up cooperation opportunities between participating companies and Nonghyup." Sopung Connect is an accelerator established in 2025, built around early-stage investment and business growth support professionals from Sopung Ventures.
Nov. 11, 2026
-
Agricultural machinery firm uses 3D printing to land W116m procurement deal
TIPA visits North Jeolla TP, agricultural machinery firm Equipment used to develop prototypes; 2 patents filed Hada posts 6.2 billion won in sales last year, averaging 27.5% annual growth since founding Hada, an agricultural machinery manufacturer based in Iksan, North Jeolla Province, has used government-supported 3D printing equipment to develop farm machinery parts and secure a procurement contract worth 116 million won ($85,600). The Korea Technology and Information Promotion Agency for SMEs announced Wednesday that President Kim Young-sin visited the Smart Manufacturing Innovation Center at North Jeolla Province Technopark and Hada on Tuesday to review outcomes from production equipment use and assess challenges faced at the company. The Smart Manufacturing Innovation Center at North Jeolla TP installed a large-format SLA 3D printer for prototype production, an MJF 3D printer for pilot mass production and a 600kV X-ray scanner through TIPA's technopark production equipment advancement support program over a two-year period beginning in 2024. Small and medium-sized enterprises in the mobility, defense, robotics and aerospace sectors use the equipment for prototype development, quality verification and safety evaluation. Hada is among the companies that have made use of the equipment. Using the MJF 3D printer for pilot mass production, the company produced prototype parts for a garlic seeder and a distribution nozzle for an electrification onion transplanter currently under development. The company subsequently signed a 116 million won procurement contract for garlic rental farm machinery under a program to promote mechanization models for field crop farming, and filed two patents. Founded in December 2012, Hada manufactures equipment that mechanizes the full cycle of garlic farming — from seeding and pest control to cutting, harvesting, drying and sorting. The company has expanded its product lineup to include ride-on cultivators and precision fertilizer spreaders, and is also developing agricultural robots. According to Hada Chief Executive Ha Jong-woo, the company posted sales of 6.2 billion won last year, reflecting average annual growth of 27.5% since its founding. The company employs 40 people. "The production equipment support is translating into prototype development and procurement contracts," Ha said. "We will continue to advance our products and technology to expand our supply chain presence in the smart farming sector." TIPA President Kim said it is important that publicly supported production equipment be put to practical use in product development and commercialization by small and medium-sized enterprises. "We will work with technoparks to ensure that equipment and technology support leads to tangible results for companies," Kim said.
Nov. 11, 2026
-
Korea Federation of SMEs opens applications for 2027 SME merit awards
Korea Federation of SMEs, Ministry of SMEs and Startups seek contributors to SME development Five categories: model SME entrepreneurs, workers, nurturing contributors and more Industrial Order of Service Merit, presidential commendations among awards to be presented The Korea Federation of SMEs and the Ministry of SMEs and Startups have launched a search for candidates for next year's SME merit awards. The Korea Federation of SMEs announced Wednesday that it is accepting applications for the 2027 SME Merit Awards jointly with the ministry, with the submission window running from Tuesday through Dec. 11. The SME merit award program is designed to identify entrepreneurs, workers and support organizations that have contributed to the development of small and medium-sized enterprises and the growth of the national economy. Awards are presented annually at the Korea SME Entrepreneurs Convention, held during SME Week in the third week of May. Applications are accepted in five categories: model SME entrepreneur (manufacturing), model SME entrepreneur (retail and service), model worker, SME nurturing contributor, and outstanding support organization or institution. Following a screening process, recipients will receive government honors — including the Industrial Order of Service Merit (gold, silver, bronze, iron and stone tower grades), the Industrial Service Medal, presidential commendations and prime ministerial commendations — as well as institutional commendations from the Minister of SMEs and Startups and the Commissioner of the Public Procurement Service. Companies listed for industrial accident disclosures, or those with disqualifying records such as violations of fair trade law, wage arrears, or national or local tax delinquency, are barred from nomination. Companies that have caused social controversy are also subject to exclusion. Applicants should check the relevant notice under the "Information Center — Federation Announcements" section of the Korea Federation of SMEs website, then submit their application forms and supporting documents by email.
Nov. 11, 2026
-
Kyung Dong Navien opens pop-up store at The Hyundai Daegu to showcase lifestyle appliances
Navien pop-up store runs Nov. 10-22 on seventh floor of The Hyundai Daegu Three experience zones cover dehumidifying air purifiers, bath care and sleep mats Fifth pop-up after Seoul, Gyeonggi Province and Daejeon stops, expanding reach to major department stores nationwide Kyung Dong Navien has opened a pop-up store in Daegu, expanding opportunities for customers to try its lifestyle appliances — including dehumidifying ventilation air purifiers, bathroom care devices and sleep mats. The company announced Wednesday that it will run the "Navien Pop-up Store" on the seventh floor of The Hyundai Daegu through Nov. 22. The store opened Tuesday and is organized so customers can experience products by living space. The pop-up features three experience zones: a dehumidifying ventilation air purifier zone centered on the Magic Plus model, a bath care zone and a sleep mat zone. In the air purifier zone, visitors can compare how perceived temperature shifts with humidity even when the actual temperature stays the same. The featured product combines dehumidifying, ventilation and air-purification functions, and highlights a "constant-temperature dehumidification" feature that maintains optimal humidity while minimizing temperature fluctuation. The zone also lets visitors experience a kitchen air-quality management system that links an induction cooktop, a 3D air hood and the dehumidifying ventilation air purifier. When the induction cooktop is in use, the 3D air hood activates automatically while the air purifier draws in fresh outside air. The bath care zone showcases four functions — dehumidifying, warm-air drying, blow-drying and exhaust — designed to control moisture and odors in the bathroom. In the sleep mat zone, visitors can try the "Sleep Mat Four Seasons" and "Sleep Mat Carbon," both of which offer cooling and heating functions. During the event, Kyung Dong Navien will also offer product consultations tailored to each customer's residential environment and lifestyle. Visitors to the experience zones will receive gifts including a "KDZ" character keyring, stickers, a biodegradable scrubber, a cooler bag and a blanket. The Daegu event is the company's fifth pop-up store, following earlier runs at The Hyundai Seoul, Hyundai Department Store's Pangyo and Apgujeong flagship locations, and Daejeon Shinsegae Art&Science. Kyung Dong Navien has been broadening its product lineup beyond its core boiler business into air quality management, bathroom care and sleep products, and is using department store pop-up stores to expand its direct touchpoints with consumers.
Nov. 11, 2026
-
Kibo launches crackdown on illegal policy finance brokers, offers up to 600,000 won in rewards
Four policy finance institutions join reporting drive running Wednesday through Dec. 8 482 illegal broker reports filed in first half of this year; 8 referred for investigation Cooperation with Korean National Police Agency strengthened; voluntary disclosure immunity also available Korea Technology Finance Corporation is launching a concentrated reporting period to root out illegal brokers who exploit the policy finance support process. The agency is raising the reward for tips to a maximum of 600,000 won ($443) and stepping up inspections and enforcement in cooperation with the Korean National Police Agency. Kibo said it will run the "Concentrated Reporting Period for Third-Party Misconduct" from Wednesday through Dec. 8. The initiative stems from discussions at the seventh meeting of the Ministry of SMEs and Startups' Third-Party Misconduct TF, held Thursday. Four policy finance institutions are participating jointly: Kibo, Korea SMEs and Startups Agency, the Korea Federation of Small and Medium Business, and the Korea Federation of Credit Guarantee Foundations. Illegal broker activity in the policy finance sector has continued to surface this year. According to the Ministry of SMEs and Startups, 482 reports were filed with the illegal broker reporting center between Jan. 1 and June 19. Of those, 412 cases, or 85.5 percent, were complaints that policy finance institutions could handle internally, while 8 cases, or 1.7 percent, were referred to investigative authorities. Another 27 cases remain under investigation. Common illegal schemes include impersonating government agencies by using official symbols without authorization to solicit policy loans, collecting upfront fees and then disappearing, and forging loan agreements and credit guarantee certificates. The Ministry of SMEs and Startups ran its first concentrated reporting period for one month starting June 29, during which it raised the reward from 400,000 won to 600,000 won. The same reward level applies to the current reporting period. Kibo plans to pay prompt small-sum rewards to tipsters who submit specific circumstances and credible evidence to the illegal broker reporting center. A voluntary disclosure immunity program will also be in place, under which companies that proactively report third-party misconduct will be reviewed for exemption from penalties. Kibo also plans to streamline the guarantee application process by reducing the amount of information customers must enter directly, making it easier for those less familiar with digital platforms to apply. "We will work closely with relevant agencies to create a fair and transparent financial support environment where businesses can access policy finance without improper interference from third parties," said Lee Jong-hyeok, executive vice president of Kibo.
Nov. 11, 2026
-
National Assembly moves to ease 'growth penalty' on small businesses
Lawmakers Ahn Cheol-soo, Jang Cheol-min introduce bills to ease support cutoffs tied to company growth Proposals include preserving stock option privileges for venture firms, introducing 5-year graduation deferral for mid-sized companies Lawmakers are pushing legislation to ease the so-called "growth penalty" — the loss of government support that companies face when they expand from small and medium-sized enterprises into mid-sized firms, or from mid-sized firms into large corporations. The bills aim to address what critics call "Peter Pan syndrome," in which companies deliberately avoid growing to retain government support. Both ruling and opposition party lawmakers have introduced related bills, and the government is separately pursuing a plan to phase out tax benefits gradually as companies grow. According to the National Assembly's bill information system, Democratic Party of Korea lawmaker Jang Cheol-min introduced a bill Friday to amend the Special Act on Promoting Growth and Strengthening Competitiveness of Mid-Sized Enterprises. The centerpiece of the bill is a "graduation deferral" system that would allow companies to retain their mid-sized enterprise status for five years even after their scale exceeds the threshold for that classification. The bill also includes provisions to extend some privileges currently available only to small and medium-sized enterprises to mid-sized firms, and to allow the establishment of a guarantee account to support mid-sized companies' fundraising. The proposal aims to reduce support gaps not only during the transition from small and medium-sized to mid-sized status, but also when mid-sized companies grow into large corporations. People Power Party lawmaker Ahn Cheol-soo also introduced a bill Friday to amend the Special Act on Fostering Venture Businesses. The bill would allow venture companies that grow into mid-sized enterprises to retain special privileges related to granting stock options and acquiring treasury shares to fulfill performance-based share award agreements. Under current law, a venture company must meet the requirements for small and medium-sized enterprise status. If a company's sales or assets grow beyond the SME threshold, its venture company certification is revoked and related privileges no longer apply. Ahn believes the share-compensation privileges should be preserved so that companies can continue to attract top talent even after growing beyond SME status. The government is also pursuing regulatory reforms to reduce abrupt support cutoffs tied to company growth. The 2026 tax reform package announced in August included plans to introduce a gradual phase-out structure for the special tax reduction for small and medium-sized enterprises and for tax credits on production costs for video and webtoon content. The measure is intended to ease the burden of companies losing tax benefits all at once as they grow. Because the reform requires amendments to relevant laws, the final scope of its application will depend on the outcome of National Assembly review. The government had earlier extended the SME graduation deferral period from three years to five and raised the sales thresholds by industry to ease the burden of scaling up. However, concerns have persisted that additional reforms are needed, as companies continue to lose support and privileges granted under individual laws once they graduate from SME status. Corporate growth has slowed in recent years. According to business demographic statistics released last month by the Ministry of Statistics, the number of high-growth companies last year fell to 4,534 — a decline of 855, or 15.9 percent, from the previous year. Among high-growth companies, so-called gazelle companies — those four to five years past their business registration — also dropped to 1,146, down 208, or 15.4 percent, from the year before. It has not been confirmed, however, whether the decline in high-growth companies resulted from reduced support programs. The number of mid-sized enterprises, meanwhile, continues to rise. According to the 2024 Mid-Sized Enterprise Basic Statistics released by the Ministry of Trade, Industry and Resources, the number of domestic mid-sized enterprises reached 6,474, up 606, or 10.3 percent, from the previous year. Some 1,275 companies entered mid-sized status through SME graduation and new establishment, while 669 exited the category due to growth into large corporations, reversion to SME status, or suspension or closure of operations.
Nov. 11, 2026
-
Cytiva sustainability leader says measured PCF data is K-bio’s survival weapon
“The era of setting and declaring sustainability targets is over. We are now in an era of execution — where carbon reductions must be demonstrated with real data.” — Ryan Walker, Senior Director of Sustainability Programs, Cytiva 라이언 워커 싸이티바 지속가능성 프로그램 총괄 시니어 디렉터 Ryan Walker, senior director of sustainability programs at global life sciences leader Cytiva, laid out a survival strategy for South Korea‘s biopharmaceutical industry amid rapidly shifting global standards — including the revision of the Science Based Targets initiative’s net-zero framework — in an exclusive interview on Tuesday. Walker said Korean biotech companies posting double-digit annual sales growth face a structural contradiction when relying on spend-based carbon estimates: the only way to reduce emissions under that method is to spend less. He said acquiring and sharing precisely measured product carbon footprint (PCF) data is the key to navigating the rising tide of global net-zero standards. Cytiva, part of Danaher Corporation, is a global life sciences solutions provider supporting customers across the biopharmaceutical development and manufacturing process. It was formally established in 2020 when the Danaher Group acquired GE Healthcare‘s life sciences division, but it carries more than 300 years of bioprocess technology heritage — including Whatman, founded in 1733; ÄKTA, the global standard for protein purification; and HyClone, a leader in cell culture. The company employs more than 15,000 people in over 40 countries, and the majority of FDA-approved biopharmaceuticals are produced using Cytiva technology. Each year, about 400 million patients receive treatments for more than 200 diseases manufactured with Cytiva’s technology. Walker, who oversees Cytiva‘s decarbonization roadmap, SBTi implementation and sustainable product design, has an unusual background. A former US Marine Corps officer, he was deployed to South Korea in 2004 and conducted joint exercises with the Republic of Korea Marine Corps. After leaving the military, he joined Bayer before moving to GE — Cytiva’s predecessor — in 2007, where he spent more than 13 years leading commercial distribution networks and customer partnerships across the United States and Canada. Walker is recognized for translating sustainability strategy into measurable operational objectives through the lens of business management, cost and process yield — not abstract environmental slogans. Returning to South Korea for the first time in 22 years, Walker said in the interview: “Just as the US and Korean Marines conducted closely coordinated joint operations back then, net zero can never be achieved by any single company acting alone. The entire supply chain — from raw material suppliers to biopharmaceutical manufacturers — must be tightly connected through data.” ‘End the spend-based contradiction’: measured PCF data will decide who wins contracts Walker described the practical impact of the SBTi standard revision — the finalization of Version 2.0 and the start of full verification — as a shift toward data precision. For years, the industry focused on announcing ambitious targets; now, with 2030 and 2035 near-term milestones approaching, concrete implementation plans and verifiable data assurance have become non-negotiable requirements. “Until now, companies have been tackling the relatively straightforward task of reducing carbon within their own operations — Scope 1 and 2,” he said. “But we have entered a phase where no single company can achieve net zero on its own, because raw material suppliers, customers and global end-clients are all linked in one chain.” In the biopharmaceutical industry, 90 to 95 percent of greenhouse gas emissions originate across the value chain — in raw material procurement, logistics and other Scope 3 activities. Cytiva has moved swiftly on Scope 1 and 2, cutting emissions at its own facilities by 55 percent against a 2021 baseline by 2025 and introducing 100 percent renewable electricity at 96 percent of its manufacturing sites. The time has now come to fundamentally overhaul how value-chain emissions are calculated. “Most of the industry currently estimates supply-chain emissions by multiplying raw material procurement spending by a carbon emission factor,” Walker said. “The fatal flaw of this spend-based calculation is that the only way to reduce emissions is to spend less money.” He added that demanding companies spend less and shrink their business is not an option for fast-growing Korean biotech firms posting double-digit annual growth. “Three years ago, Cytiva stopped using estimated figures and began physically measuring the carbon actually generated in product manufacturing and processing — transitioning to what we call physical data,” he said. Walker said the top request from key customers he met during this week‘s visit was for Cytiva to share its measured PCF data. “Only by securing precise PCF data can Korean companies transparently understand their supply-chain emissions and proactively respond to the rigorous supply-chain due diligence demanded by global big pharma,” he said. In the coming global competition for biotech contracts, the speed and accuracy with which a supplier can provide measured PCF data will become the defining differentiator and a critical barrier to entry, he added. ‘Sustainability being costly is a misconception’: logistics shift saves $3 million Walker was equally direct in pushing back against concerns raised in parts of the biopharmaceutical industry about the cost of transitioning to greener processes — the so-called green premium — and the burden of GMP revalidation. “The idea that sustainability adds costs and conflicts with business is a clear misconception,” he said. “What is good for business is good for the environment, and the two can be a complete win-win.” “Sustainability is not complicated. It comes down to two principles: do less and do better,” he said. “Using fewer resources and less energy cuts costs and reduces supply-chain risk, building resilience. Innovating smarter designs means you can deliver safe treatments to patients faster with fewer resources.” Real cost savings back up the argument. Walker said Cytiva worked with a global customer to restructure its logistics network, shifting raw material procurement away from distant factories to the nearest regional manufacturing hub. “Through that collaboration, the customer saved more than $3 million in shipping costs and simultaneously eliminated thousands of tons of carbon emissions,” he said. Cytiva is also making technical breakthroughs on process waste and chemical regulation. On single-use plastics — widely used in bioprocessing given the paramount importance of sterility and safety — Walker said they remain environmentally superior to stainless steel when washing water, chemicals and power consumption are factored in, but that plastic waste cannot simply be left unaddressed. Cytiva is running a near-term program with specialist firm Polycarbin to collect and recycle laboratory plastics regardless of manufacturer. It is also conducting joint research with the University of Wisconsin-Madison on solvent-targeted recovery and precipitation, or STRAP, technology — an advanced recycling method that chemically breaks down used plastics layer by layer and reconstitutes them to their original structure, with the goal of enabling an infinite circular cycle for bioprocess plastics. On per- and polyfluoroalkyl substances, where regulation is tightening in Europe and the United States, Walker said Cytiva has commercialized a PFAS-free lineup including Supor Prime, a new filter product for sterile environments. “Just as quality, safety and data security passed through years of cost debate before becoming table stakes in business operations today, sustainability will also move beyond short-term cost arguments to become the baseline standard that determines whether a bio business survives,” he added. Songdo hub to recycle 60–80% of process water: ‘Korean bio must lead the global supply chain’ Cytiva‘s Korea Innovation Hub, a 6,100-square-meter facility under construction in Songdo, Incheon, is the strategic anchor where the company’s global net-zero framework takes concrete shape on Korean soil. The Songdo hub has applied the company‘s rigorous “net-zero environmental impact” standards from the design stage, including maximizing energy efficiency and achieving zero landfill waste. “Korea is one of Cytiva‘s three key global strategic markets and its fastest-growing,” Walker said. “The Songdo hub is being built with an eco-friendly water treatment facility that will purify and recycle 60 to 80 percent of the water used in filter production on-site. It will serve as a model showcase for sustainable manufacturing across the Asia-Pacific region.” When the Songdo manufacturing center begins full-scale production of filtration products for biopharmaceuticals — a core raw material — in the first half of 2027, Korean and Asian biotech companies will be able to source those materials locally rather than depending on long-haul air freight. That is expected to directly reduce customers‘ Scope 3 carbon emissions while dramatically improving supply-chain stability and resilience. As global sustainability standards and requirements continue to rise, Walker urged Korean biopharmaceutical and contract development and manufacturing organization companies to move beyond being passive followers and become global agenda-setters. “Six years ago, sustainability discussions were driven by large pharmaceutical companies in Europe and the United States, and Asian companies barely registered on the radar,” he said. “In just four to five years, Korean companies — led by Samsung Biologics — have been at the forefront of raising supply-chain standards.” “Korean biotech companies must never underestimate the strong influence they hold within the global sustainability framework,” he added. “They should demand more forcefully from global life sciences suppliers and solutions providers like Cytiva, asking for 2035 and 2050 reduction roadmaps and measured data, and proactively propose joint projects that deliver real, on-the-ground carbon reductions.” “In a world where the sustainability landscape is changing rapidly, if Korean companies set high standards and take the lead, that will become the most powerful weapon for securing an unassailable competitive edge in the global market,” Walker said.
Nov. 11, 2026
-
M&Wise CEO Jo Jong-cheol aims for 10,000 global clients by 2030
From one-person startup to nearly 40 billion won in annual sales over 20 years Integrated messaging solution supplied to 95% of domestic banks 15,000 corporate accounts; 1,000 direct-contract clients Sales of 35.5 billion won last year; 40 billion won targeted this year Mobile e-documents, cloud and AI identified as next growth drivers "Our goal is to build solutions and services used by 10,000 companies worldwide by 2030." Jo Jong-cheol, CEO of M&Wise, shared that ambition in a recent interview. Jo founded the company alone in 2004 and has since grown it into a messaging specialist with annual sales approaching 40 billion won ($29.5 million). The plan is to expand the current base of roughly 1,000 direct-contract clients to 10,000 by 2030. M&Wise provides integrated messaging solutions and services that help businesses manage the emails, text messages and KakaoTalk notification messages they send to customers. According to Jo, the company supplies its integrated messaging solution suite, wiseU, to 95 percent of banks in South Korea, and roughly half of all insurers, securities firms and credit card companies also use M&Wise products. Jo moved into the messaging business in earnest in 2007. Drawing on his experience co-founding a personalized email marketing solution company in 1998, he set up a one-person firm in 2004 that initially provided systems integration consulting to banks. He later acquired his former co-founded company and pivoted to messaging, having noticed the growing variety of channels — text messages, mobile push notifications and others — through which businesses were reaching customers. "Starting from email technology suited to personalized marketing, I saw the potential of a unified messaging system that could bring together text messages and mobile push notifications," Jo said. "I wanted to develop the messaging technology businesses needed and carve out the market myself." Pivot to Kakao business messaging puts sales within reach of 40 billion won The turning point for M&Wise came in 2016, when the company moved beyond its solution-sales model and expanded into Kakao business messaging services, establishing a more stable revenue base. "Our existing solution business was highly dependent on whether we landed large projects, which made earnings volatile," Jo said. "We expanded into service businesses such as Kakao business messaging to secure steadier sales." The company now supplies solutions to more than 150 businesses and institutions, including SK Telecom, the National Health Insurance Service, Korea Post and Korail. Corporate accounts using its Kakao-related services have surpassed 15,000. Sales last year reached 35.5 billion won, and the company expects to break through 40 billion won this year. Jo cited the company's proprietary technology as the core of its competitiveness. Projects with KB Kookmin Bank and SK Telecom stand out as proof of that capability, Jo said, noting that meeting the demanding requirements of financial institutions and telecoms — which must send messages to vast numbers of customers — validated the performance and reliability of M&Wise's products. Mobile e-documents and cloud to drive business expansion M&Wise is looking to mobile electronic documents as a new growth engine. The business involves converting the paper mail that financial institutions and companies send to customers into electronic documents and mobile registered mail. "A single insurer can send out 300 to 400 different types of postal mail," Jo said. "This year we began working with banks, securities firms and insurers on digitizing their paper correspondence." The company is also weaving AI into its operations. It recently used AI to conduct legal reviews of mobile messages that a bank sends to customers, and has launched a service that uses AI to create image and message templates. Jo also acknowledged that AI could reshape the existing solution market. "As AI makes development easier, the market for traditional solution providers could shrink," he said, adding that adapting to technological change is essential. Jo identified enterprise cloud services as another pillar of future growth. M&Wise already offers its messaging solutions as a cloud service, though that business remains small. "Building out the enterprise cloud market could become the foundation for future growth," Jo said, expressing his intention to expand through partnerships with large companies such as KT Corp. Jo also spoke about what he calls "happiness management" — creating a workplace where employees want to stay for the long term. M&Wise runs a "Happy Workplace Committee" through which staff can voice opinions on welfare and company events. "My goal is to build a company that shares results with its employees and grows together with them," Jo said.
Nov. 11, 2026
-
GC Biopharma takes its 60-year blood-products legacy into the heart of America
ALYGLO direct sales take hold in US, targeting $150 million in annual revenue Eight plasma centers acquired to build vertically integrated supply chain Domestically produced albumin replaced imports; first Korean pharma to hit $10 million in exports in 1979 Anthrax vaccine Varithrax, 28 years in the making, completes national stockpile Technology deals with Lilly and BioMarin drive third-quarter net profit surge to 208.5 billion won When a nation faces crisis, the last line of defense protecting its people is not weapons — it is medicine. Every time the world has scrambled to secure vaccines, GC Biopharma has manufactured the shots itself. In a divided country living under the threat of biochemical attack, it has pushed through the domestic production of essential stockpile drugs. Since its founding in 1967, the company's nearly six decades of work have amounted to more than the profit-seeking of an ordinary pharmaceutical firm — they represent a sustained effort to establish South Korea's sovereign control over its own health security. The same determination that domesticated albumin — a blood-fraction product previously imported in its entirety — and made GC Biopharma the first Korean pharmaceutical company to surpass $10 million in exports in 1979 is now surging again, this time on the most fiercely contested pharmaceutical battlefield in the world: the United States. Having cracked open the American blood-products market — long monopolized by a handful of multinational giants — with its immunoglobulin ALYGLO, the company has since closed a string of trillion-won mega-deals with global pharmaceutical majors, launching what it describes as its ascent to the ranks of the world's top-tier biotech firms. ALYGLO breaks into the US market, racing toward $150 million in its third year At the forefront of GC Biopharma's global push stands ALYGLO, its intravenous immunoglobulin. In late 2023, ALYGLO became the first Korean-made blood product to receive US Food and Drug Administration approval, marking a milestone in the history of Korean biotech. Blood-fraction products — biopharmaceuticals derived by fractionating and purifying human plasma — demand extraordinarily complex manufacturing processes and rigorous current Good Manufacturing Practice inspections, making the segment a near-impenetrable domain dominated by a small number of global pharmaceutical majors. GC Biopharma broke through with a proprietary purification technology developed in-house: a cation exchange chromatography process that filters out more than 99 percent of Factor XIa, a coagulation factor linked to the potentially fatal thromboembolic events that can occur during blood-product infusions, delivering a level of purity and safety that set it apart from rivals. The results speak in numbers. ALYGLO generated $36 million in US sales in the second half of 2024, its first year on the American market. That figure surged 194 percent to $106 million in 2025, clearing the $100 million mark in a single leap. Now in its third year on the market, the product is on track to grow more than 40 percent this year, putting annual sales of $150 million within reach. A rigorous direct-sales strategy in the United States has been central to that success. Through its US subsidiary GC Biopharma USA, the company signed contracts directly with major pharmacy benefit managers, securing patient access covering more than 75 percent of the entire US insurance market. It also built a tightly woven local distribution network spanning specialty pharmacies and large clinics, minimizing intermediary margins and maximizing profitability. Vertical integration from raw plasma to finished product — and a $1 billion ambition with next-generation SCIG ALYGLO's momentum in the United States is not a short-term story. GC Biopharma has built what it calls a full blood-products value chain — integrating raw plasma procurement, finished-product manufacturing and local sales into a single end-to-end operation — to lay the foundation for a sustained competitive advantage. The biggest bottleneck in the blood-products business is a reliable supply of source plasma. To solve that problem, the company acquired ABO Holdings, which operates eight plasma collection centers across the United States. Through key plasma centers in New Jersey, Utah, California and Texas, GC Biopharma plans to raise the share of self-sourced plasma from 14 percent in 2025 to 80 percent by 2028. The strategy is to eliminate supply uncertainty, lower procurement costs and push ALYGLO's operating profit margin above 30 percent over the medium to long term. The company has also identified a 20 percent subcutaneous immunoglobulin, or SCIG, as its next major growth engine. The intravenous immunoglobulin formulations that currently dominate the US market require patients to visit a hospital every three to four weeks for infusions lasting several hours. High-concentration SCIG, by contrast, can be self-administered at home — a significant advantage for patients. By 2030, SCIG is projected to account for more than 30 percent of the US immunoglobulin market, and it commands a premium price roughly 1.5 times that of intravenous formulations, making it a high-margin segment. GC Biopharma has developed a proprietary high-yield manufacturing process that improves process yield 1.6 times over ALYGLO's current process and increases annual plasma processing capacity 3.5-fold. The company has begun expanding a dedicated SCIG production line at its Ochang factory in North Chungcheong Province, using available space within the existing facility. It plans to file an investigational new drug application for a US Phase 3 trial in 2027, complete the factory expansion in 2029 and begin commercial sales in 2031. The long-term blueprint is to complete a dual portfolio of intravenous and subcutaneous immunoglobulins and generate more than $1 billion in annual US sales alone. From urine collection buckets to domestically produced albumin — 60 years built on blood and sweat Behind this global ambition lies a history that is, in itself, the story of how South Korea built its biopharmaceutical industry from scratch. Younger generations may not know it, but in the 1970s and 1980s, public restrooms at schools and parks across the country displayed plastic urine collection containers bearing the GC Biopharma logo. The company was gathering urine from the entire population to extract the raw material for urokinase, a thrombolytic agent used to treat strokes and heart attacks — an episode that has become the defining symbol of its relentless drive to produce medicines domestically. Overcoming severe constraints on raw material supply, GC Biopharma domesticated albumin — a blood-fraction product that had been imported entirely — and established itself as the definitive name in Korean albumin production. That achievement made it the first Korean pharmaceutical company to surpass $10 million in exports in 1979. It followed that with the world's third hepatitis B vaccine, Hepavax, in 1983, and then the world's first hemorrhagic fever with renal syndrome vaccine, Hantavax, cementing its place among the global leaders in blood products and vaccines. While most domestic pharmaceutical companies remained distributors — selling generic copies or licensed products from multinational firms — GC Biopharma stayed the course in the demanding field of biopharmaceuticals. In 2015, it crossed 1 trillion won ($738 million) in annual sales, driven by its own vaccines and blood products. Without the benefit of high-profile advertising, it has maintained its position as the second-largest pharmaceutical company in South Korea by sales, sustained entirely by its technological edge in a market with few competitors. Inside the anthrax wing at the Hwasun factory in South Jeolla Province — a national shield forged over 28 years The most tangible expression of that heritage is the anthrax wing at GC Biopharma's vaccine plant in Hwasun, South Jeolla Province. Stepping into the 990-square-meter dedicated manufacturing facility — set apart from the production lines for the influenza vaccine GC Flu and the varicella vaccine Varicella — the hum of heavy machinery fills the air alongside the clean sterility of a controlled environment. Built at a cost of 10 billion won and brought into operation last year after a long wait, it is the world's first dedicated production site for a recombinant protein anthrax vaccine: Varithrax. The facility is South Korea's last strategic line of defense against the threat of anthrax bioterrorism, a pathogen with a respiratory fatality rate approaching 97 percent. Only a handful of countries in the world — among them the United States and the United Kingdom — are capable of producing anthrax vaccines domestically. South Korea had previously relied entirely on imported anthrax vaccines, leaving it unable to stockpile as much as it needed and vulnerable to price gouging. With the Hwasun anthrax wing now fully operational, the country can produce up to 10 million doses per year — enough to cover about 2.5 million people — giving it an independent defensive capability for the first time. The journey took 28 years. Foundational research begun in 1997 at what was then the National Institute of Health — now the Korea Disease Control and Prevention Agency — was handed to GC Biopharma in 2002, which then carried it through process development and clinical trials. Where existing foreign vaccines used whole non-pathogenic anthrax bacteria and carried a residual risk of trace toxin side effects, Varithrax purifies only the protective antigen protein from the anthrax toxin, maximizing safety. Designated as South Korea's 39th domestically developed new drug, it received the grand prize at the Korea New Drug Development Awards, demonstrating its technological credentials on the world stage. The completion of the national stockpile transition — replacing all imported anthrax vaccines with the domestic product as the imported supply's shelf life expired — stands as a testament to the company's conviction that it must make medicines that are difficult to produce but indispensable to humanity. Big pharma lines up for open innovation — rare disease and vaccine deals deliver jackpots GC Biopharma's transformation in research and development is also showing up in a string of global licensing deals. Moving beyond its earlier model of distribution agreements and minority stakes in biotech ventures, the company has combined its proprietary platform technologies with deep pharmaceutical manufacturing expertise to close a series of high-value international deals. The most prominent is the out-licensing of LA-GLA (also known as GC1134A or HM15421), a next-generation Fabry disease treatment co-developed with Hanmi Pharm. In October, the two companies signed a global exclusive license agreement with rare-disease specialist BioMarin worth up to $475 million. The deal brought together Hanmi Pharm's long-acting drug platform technology and GC Biopharma's enzyme replacement therapy expertise, accumulated through the commercialization of Hunterase, the world's second approved treatment for Hunter syndrome. Particularly notable was the upfront payment: roughly 15 percent of the total deal value, or $70 million, was secured as a non-refundable payment despite the program being in the early Phase 1/2 stage — a clear signal of the technology's competitive standing. The deal has been credited with broadening the export horizons of Korean biotech beyond the oncology and obesity treatments that have dominated recent licensing activity, into the rare and intractable disease space. Earlier, in May, the sale of US affiliate Curevo Vaccine drew wide praise from the biotech industry. Eli Lilly acquired Curevo's entire share capital for up to $1.5 billion, and GC Biopharma, which held a 20.3 percent stake in Curevo, received a substantial upfront cash payment. The arrangement went well beyond a simple equity gain. GC Biopharma structured a multi-layered cash flow — milestone payments tied to the development of a next-generation shingles vaccine, royalties proportional to post-commercialization sales, and CMO revenue from future finished-product supply. Restructuring for the 3 trillion won club — AI-integrated mRNA to secure the next growth frontier The growth of its core business and the proceeds from global deals have dramatically improved the company's financial position. Consolidated sales rose 18.5 percent from 1.68 trillion won in 2024 to 1.99 trillion won in 2025, driven by the full-scale ramp-up of ALYGLO's US sales and growth across key product lines. Operating profit surged 115.3 percent to 69.1 billion won. In the third quarter of 2026, the confirmed upfront payment from the Curevo sale flowed in, pushing consolidated quarterly net profit for the period to 208.5 billion won — a more than 1,000 percent increase from the same period a year earlier — and substantially strengthening the company's balance sheet. The large cash reserves generated are being reinvested in future research and development, establishing a virtuous cycle. GC Biopharma's attention has now turned to a proprietary mRNA-LNP platform and next-generation modalities. Working with the Mogam Institute for Biomedical Research, the company has developed an mRNA sequence optimization technology that uses AI algorithms to improve protein translation efficiency by more than 50 percent compared with global benchmarks. It has also filed patents on eight high-expression lipid nanoparticle formulations and four organ-targeted LNP formulations, and has completed an end-to-end production infrastructure at its Hwasun factory in South Jeolla Province — covering candidate discovery, synthesis, LNP formulation and finished-product manufacturing entirely in-house. The first product from this platform, a COVID-19 mRNA vaccine (mCOVID, GC4006A), recently completed dosing of its first patient in a Phase 2 trial, keeping the government-backed vaccine self-sufficiency program on track. The company has also begun developing a next-generation in vivo CAR-T therapy in collaboration with Abclon — a treatment designed to generate CAR-T cells directly inside the patient's body without extracting cells — accelerating its evolution into a cutting-edge biotech spanning oncology and rare diseases. A 60-year journey that began with developing essential medicines for underserved patients is now translating into a major leap: direct sales in the United States and the global export of novel drugs. "Our founding spirit — developing medicines that are difficult to make but indispensable to humanity — has not changed," a GC Biopharma official said. "Building on the success of ALYGLO and an advanced R&D pipeline, we will grow into a global total healthcare leader that transforms the lives of patients with rare and intractable diseases around the world."
Nov. 11, 2026
- 1Malaysia's BE International brings 1,500-strong incentive tour to Korea, bypassing Turkey
- 2AI singer tops Melon chart for first time with 'Did You Become the Adult You Dreamed Of?'
- 3Jensen Huang's daughter took the photo of him embracing his alleged mistress
- 4Man beat live-in girlfriend 514 times over 3 hours, killing her; forensic expert says footage was too disturbing to watch
- 5Crosswalk at Cheonggyecheon 6-ga intersection opens after 20 years of resident demands
- 6'A concert is a ritual for the soul': Currentzis makes long-awaited Korea debut after six years
-
WORLD
US warns of punishment for anyone enabling Iran's Strait of Hormuz toll scheme
-
INDUSTRY
Toyota union puts productivity first; Hyundai Motor union demands bigger share of profits
-
FINANCE
National Growth Fund to invest $531M in FuriosaAI, which rebuffed Meta's $800M takeover bid
-
INDUSTRY
Korea Shipowners' Association holds amateur baduk tournament for Maritime Day
